Stefanie Petrou Binder, MD
Multidrug-resistant E. coli common prior to prostate biopsy
In men scheduled for transrectal prostate biopsy, 70% of the fluoroquinolone-resistant Escherichia coli isolated from fecal flora represented the epidemic, multidrug-resistant ST131 strain, a recent phylogenic and virulence factor analysis found.
Phosphodiesterase type-5 inhibitors found safe, efficacious for lower urinary tract symptoms
Phosphodiesterase type-5 inhibitors are safe and effective, alone or in combination with alpha-blockers, against lower urinary tract symptoms secondary to BPH, according to a recent systematic review and meta-analysis.
Laparoendoscopic single-site radical nephrectomy shows no clinical advantage
A recent study revealed that the use of laparoendoscopic single-site surgery to perform radical nephrectomy is just as effective as conventional laparoscopic radical nephrectomy, attaining excellent surgical and post-surgical outcomes.
BPH surgery complications underestimated in trials
Practice complication rates following surgical treatment for BPH are higher than indicated by clinical trials, according to a recent study.
Antibiotic prophylaxis beneficial in percutaneous nephrolithotomy patients
Antibiotic prophylaxis appears to be beneficial in patients undergoing percutaneous nephrolithotomy.
Data show low morbidity of high-intensity focused ultrasound in short-term trials
Recent studies from around the world provide encouraging evidence of the safety of high-intensity focused ultrasound (HIFU) as a minimally invasive treatment for localized prostate cancer.
Prostatectomy found efficacious in high-risk prostate cancer
The authors of a study reported cancer-specific and overall survival rates of 96% and 94%, respectively, at 5 years in men with high-risk prostate cancer who underwent radical prostatectomy.
Surveillance viable in carefully selected prostate cancer patients
Active surveillance appears to be a safe option for carefully selected patients diagnosed with prostate cancer. However, changes in biopsy scheduling and technique may be needed to detect high-grade cases.
Alpha-blocker, antimuscarinic efficacious in male lower urinary tract symptoms
Combination therapy consisting of an alpha-blocker and antimuscarinic agent is more effective in treating lower urinary tract symptoms in men with BPH than antimuscarinic monotherapy.
Combination therapy safe, efficacious in erectile dysfunction, lower urinary tract symptoms
Combined treatment with the alpha-1 receptor antagonist alfuzosin (Uroxatral) and a low dose of the phosphodiesterase type-5 inhibitor udenafil (not available in the U.S.) once daily is both safe and effective in patients with ED and LUTS.


View Results